12:00 AM
May 14, 2012
 |  BC Week In Review  |  Company News  |  Deals

Nuevolution, Boehringer Ingelheim deal

Nuevolution received an undisclosed milestone payment from Boehringer Ingelheim under a 2011 deal to use Nuevolution's Chemetics fragment-based screening drug discovery...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >